These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 21572303

  • 1. Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).
    Gonzalez E, Ballana E, Clotet B, Esté JA.
    AIDS; 2011 Aug 24; 25(13):1557-83. PubMed ID: 21572303
    [Abstract] [Full Text] [Related]

  • 2. Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1.
    González-Ortega E, Ballana E, Badia R, Clotet B, Esté JA.
    Antiviral Res; 2011 Dec 24; 92(3):479-83. PubMed ID: 22027647
    [Abstract] [Full Text] [Related]

  • 3. Reduced Susceptibility to VIRIP-Based HIV-1 Entry Inhibitors Has a High Genetic Barrier and Severe Fitness Costs.
    Müller JA, Glöckle A, Gawanbacht A, Geyer M, Münch J, Kirchhoff F.
    J Virol; 2018 Sep 01; 92(17):. PubMed ID: 29925662
    [Abstract] [Full Text] [Related]

  • 4. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
    Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.
    Cell; 2007 Apr 20; 129(2):263-75. PubMed ID: 17448989
    [Abstract] [Full Text] [Related]

  • 5. Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide.
    Forssmann WG, The YH, Stoll M, Adermann K, Albrecht U, Tillmann HC, Barlos K, Busmann A, Canales-Mayordomo A, Giménez-Gallego G, Hirsch J, Jiménez-Barbero J, Meyer-Olson D, Münch J, Pérez-Castells J, Ständker L, Kirchhoff F, Schmidt RE.
    Sci Transl Med; 2010 Dec 22; 2(63):63re3. PubMed ID: 21178138
    [Abstract] [Full Text] [Related]

  • 6. An optimized MM/PBSA virtual screening approach applied to an HIV-1 gp41 fusion peptide inhibitor.
    Venken T, Krnavek D, Münch J, Kirchhoff F, Henklein P, De Maeyer M, Voet A.
    Proteins; 2011 Nov 22; 79(11):3221-35. PubMed ID: 21989940
    [Abstract] [Full Text] [Related]

  • 7. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
    Nameki D, Kodama E, Ikeuchi M, Mabuchi N, Otaka A, Tamamura H, Ohno M, Fujii N, Matsuoka M.
    J Virol; 2005 Jan 22; 79(2):764-70. PubMed ID: 15613304
    [Abstract] [Full Text] [Related]

  • 8. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
    Su C, Melby T, DeMasi R, Ravindran P, Heilek-Snyder G.
    J Clin Virol; 2006 Aug 22; 36(4):249-57. PubMed ID: 16765082
    [Abstract] [Full Text] [Related]

  • 9. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardière JL, Pacanowski J, Meynard JL, Hance AJ, Clavel F, Mammano F.
    J Virol; 2006 Sep 22; 80(17):8807-19. PubMed ID: 16912327
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
    Izumi K, Nakamura S, Nakano H, Shimura K, Sakagami Y, Oishi S, Uchiyama S, Ohkubo T, Kobayashi Y, Fujii N, Matsuoka M, Kodama EN.
    Antiviral Res; 2010 Aug 22; 87(2):179-86. PubMed ID: 20438763
    [Abstract] [Full Text] [Related]

  • 12. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
    Moseri A, Biron Z, Arshava B, Scherf T, Naider F, Anglister J.
    FEBS J; 2015 Dec 22; 282(24):4643-57. PubMed ID: 26432362
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Targeting the sticky fingers of HIV-1.
    Blumenthal R, Dimitrov DS.
    Cell; 2007 Apr 20; 129(2):243-5. PubMed ID: 17448985
    [Abstract] [Full Text] [Related]

  • 16. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K, Shishido A, Root MJ.
    J Biol Chem; 2009 Feb 06; 284(6):3619-27. PubMed ID: 19073602
    [Abstract] [Full Text] [Related]

  • 17. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC.
    Araújo LA, Junqueira DM, de Medeiros RM, Matte MC, Almeida SE.
    J Clin Virol; 2012 May 06; 54(1):6-10. PubMed ID: 22336085
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Selection of T1249-resistant human immunodeficiency virus type 1 variants.
    Eggink D, Baldwin CE, Deng Y, Langedijk JP, Lu M, Sanders RW, Berkhout B.
    J Virol; 2008 Jul 06; 82(13):6678-88. PubMed ID: 18434391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.